Astellas, Theravance Get U.S. Approval With Vibativ, But HAP Indication Could Be Pushed To 2010
This article was originally published in PharmAsia News
Executive Summary
Japan's Astellas and Theravance's Vibativ (telavancin) gained U.S. FDA approval Sept. 11 for complicated skin infections, but an indication that will more sharply differentiate the drug may not see action until early 2010